RIPK1 and myeloid sarcoma: Similar to previous reports (Ofengeim et al., 2015; Yoshikawa et al., 2018), we show RIPK1 kinase inhibition attenuates disease in the C57BL/6 experimental autoimmune encephalomyelitis (EAE) model of MS.